Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma

Cancer Gene Therapy

Volumn 13, Issue 7, 2006, Pages 664-675

  Brin, E ^a   Atencio, I ^a   Helmich, B K ^a   Maneval, D ^a   LaFace, D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

4T1 mammary carcinoma; Antitumor efficacy; Hybrid interferon; Interferon ; Metastasis

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA INTERFERON DERIVATIVE; ALPHA2B INTERFERON; GENE PRODUCT; HYBRID PROTEIN; INTERFERON; INTERFERON ALPHA 2ALPHA 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SOLID TUMOR; TRANSGENE; TUMOR GROWTH; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY; INTERFERON ALFA-2B; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; RECOMBINANT FUSION PROTEINS;

ADENOVIRIDAE;

EID: 33747621382     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700942     Document Type: Article

References (58)

1. Pestka S. The human interferon alpha species and receptors. Biopolymers 2000; 55: 254-287.
2. Joshua DE, MacCallum S, Gibson J. Role of alpha interferon in multiple myeloma. Blood Rev 1997; 11: 191-200.
3. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 2004; 9: 9.
4. Herberman RB. Effect of alpha-interferons on immune function. Semin Oncol 1997; 24:S9-S78-S79-S80.
5. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-15628.
6. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-249.
7. Rodriguez-Villanueva J, McDonnell TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha. Int J Cancer 1995; 61: 110-114.
8. Li C, Chi S, He N, Zhang X, Guicherit O, Wagner R et al. IFNalpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene 2004; 23: 1608-1617.
9. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983; 3: 22-31.
10. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405.
11. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 1978; 38: 3174-3181.
12. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486-1493.
13. Rehberg E, Kelder B, Hoal EG, Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 1982; 257: 11497-11502.
14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
15. Ahmed CM, Wills KN, Sugarman BJ, Johnson DE, Ramachandra M, Nagabhushan TL et al. Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice. J Interferon Cytokine Res 2001; 21: 399-408.
16. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM et al. Purification of a type 5 recombinant adenovirus encoding human p53by column chromatography. Hum Gene Ther 1995; 6: 1403-1416.
17. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG et al. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 1997; 8: 453-465.
18. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y et al. Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 2004; 41: 782-789.
19. Maellaro E, Pacenti L, Del Bello B, Valentini MA, Mangiavacchi P, De Felice C et al. Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis. Br J Dermatol 2003; 148: 1115-1124.
20. Moro A, Perea SE, Pantoja C, Santos A, Arana MD, Serrano M. IFNalpha 2b induces apoptosis and proteasome-mediated degradation of p27Kip1 in a human lung cancer cell line. Oncol Rep 2001; 8: 425-429.
21. Yanai Y, Horie S, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M et al. Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro. J Interferon Cytokine Res 2001; 21: 1129-1136.
22. Legrand A, Vadrot N, Lardeux B, Bringuier AF, Guillot R, Feldmann G. Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation. Liver Int 2004; 24: 149-160.
23. Takemoto Y, Yano H, Momosaki S, Ogasawara S, Nishida N, Kojiro S et al. Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo. Clin Cancer Res 2004; 10: 7418-7426.
24. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001; 33: 346-356.
25. Ziske C, Nagaraj S, Marten A, Gorschluter M, Strehl J, Sauerbruch T et al. Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice. J Interferon Cytokine Res 2004; 24: 490-496.
26. Grebenova D, Kuzelova K, Fuchs O, Halada P, Havlicek V, Marinov I et al. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol Dis 2004; 32: 262-269.
27. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004; 80: 85-93.
28. Rahman A, Tsai V, Goudreau A, Shinoda JY, Wen SF, Ramachandra M et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther 2001; 3: 768-778.
29. Nagao S, Kuriyama S, Okuda H, Tominaga K, Nakatani T, Tsujinoue H et al. Adenovirus-mediated gene transfer into tumors: evaluation of direct readministration of an adenoviral vector into subcutaneous tumors of immunocompetent mice. Int J Oncol 2001; 18: 57-65.
30. Tagliaferri P, Caraglia M, Budillon A, Marra M, Vitale G, Viscomi C et al. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother 2004; 8: 8.
31. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S et al. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 1987; 27: 432-435.
32. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390-399.
33. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1: 372-378.
34. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-409.
35. Alizadeh H, Howard K, Mellon J, Mayhew E, Rusciano D, Niederkorn JY. Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest Ophthalmol Vis Sci 2003; 44: 3042-3051.
36. Brown JL, Barsoum J, Qin XQ. CD4+ T helper cell-independent antitumor response mediated by murine IFN-beta gene delivery in immunocompetent mice. J Interferon Cytokine Res 2002; 22: 719-728.
37. Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D et al. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 2001; 8: 497-505.
38. Choi EA, Lei H, Maron DJ, Mick R, Barsoum J, Yu QC et al. Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Clin Cancer Res 2004; 10: 1535-1544.
39. Hendren SK, Prabakaran I, Buerk DG, Karakousis G, Feldman M, Spitz F et al. Interferon-beta gene therapy improves survival in an immunocompetent mouse model of carcinomatosis. Surgery 2004; 135: 427-436.
40. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR et al. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004; 127: 123-130.
41. Lu W, Fidler IJ, Dong Z. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon beta gene therapy. Cancer Res 1999; 59: 5202-5208.
42. Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001; 61: 6201-6212.
43. Odaka M, Wiewrodt R, DeLong P, Tanaka T, Zhang Y, Kaiser L et al. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol Ther 2002; 6: 210-218.
44. Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther 2001; 4: 356-364.
45. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998; 95: 14411-14416.
46. Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001; 108: 83-95.
47. Zhang F, Lu W, Dong Z. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res 2002; 8: 2942-2951.
48. Brierley MM, Fish EN. Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res 2002; 22: 835-845.
49. Indraccolo S. Undermining tumor angiogenesis by gene therapy: an emerging field. Curr Gene Ther 2004; 4: 297-308.
50. Ahmed CM, Sugarman BJ, Johnson DE, Bookstein RE, Saha DP, Nagabhushan TL et al. In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery. Hum Gene Ther 1999; 10: 77-84.
51. Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN et al. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther 2001; 8: 788-795.
52. Santodonato L, Ferrantini M, Palombo F, Aurisicchio L, Delmastro P, La Monica N et al. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Ther 2001; 8: 63-72.
53. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004; 10: 525-532.
54. de Castro FA, Palma PV, Morais FR, Simoes BP, Carvalho PV, Ismael SJ et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 2003; 44: 2061-2067.
55. Tough DF. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 2004; 45: 257-264.
56. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumour growth and metastasis in beige mice. Nature 1980; 284: 622-624.
57. Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Ahmed CM, Lau JY et al. Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol 2002; 180: 36-42.
58. Demers GW, Johnson DE, Machemer T, Looper LD, Batinica A, Beltran JC et al. Tumor growth inhibition by interferon-alpha using PEGylated protein or adenovirus gene transfer with constitutive or regulated expression. Mol Ther 2002; 6: 50-56.